DOCSLIB.ORG

Laws of Fiji

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

LAWS OF FIJI CHAPTER 115 PHARMACY AND POISONS Cap . 115 Rev. 1985 Pharmacy and Poisons 3 CHAPTER 115 PHARMACY AND POISONS TABLE OF PROVISIONS PART I-PRELIMINARY SECTION 1 . Short title 2. Interpretation 2A. Meaning of "medicine" and related expressions 2a. Certain substances or articles to be treated as medicines 3. Meaning of "sale" 4. Meaning of "adulteration" PART II-ADMINISTRATION 5. The Pharmacy and Poisons Board 6. Members of Board 7. Meetings of the Board 8. Board may summon person to attend and give evidence 9. Chairman may administer oath 10. Person failing to appear when summoned 11. Person refusing to .make oath or affirmation 12. False testimony 13. Liability of members 14. Fees 15. Power of search 16. Secretary. Inspectors 17. Persons eligible for appointment as inspectors 18. Powers of inspectors 19. Certificate of Government analyst PART III-PHARMACISTS 20. Register of Pharmacists 21. Pharmacists how registered 22. Persons eligible for registration 23. Board may direct examination of applicant 24. Registration of applicants 25 . Appeal against refusal of Board to register 26. Copy of register to be published 27. Fraudulent representation 28. Amendments may be made in register 4 Pharmacy and Poisons Cap. 115 Rev. 1985 29. Notification of change of address or death 30. Correction of register 31 . Corporate body may carry on business of pharmacist 32. Restriction on number of pharmacies 32A . Establishment of Fiji Pharmaceutical Society 32B. Objects of Fiji Pharmaceutical Society 32c . Former Fiji Pharmaceutical Society PART IV-CONDUCT OF BUSINESS AS PHARMACIST 33. Grounds of cancellation of registration 34. Removal of name from register 35. Surrender of certificate of registration 36. Persons other than registered pharmacists not to carry on business 37. Death, unsoundness of mind or bankruptcy of pharmacist 38. Name of pharmacist to be exhibited 39. Pharmacists only to dispense 40. Temporary licence 41. Prescriptions to be signed 42. Record of prescriptions 43. Conduct of business by pharmacist 44. Medical practitioners, etc., may dispense 45. Automatic machines for vending medicines prohibited 46. Restrictions on supply of certain medicines 47. False or misleading advertisements 47A. Prohibition of certain advertisements 47B. Meaning of "advertisement" in sections 47 and 47A 48. British Pharmacopoeia PART V-MANUFACTURE, SALE AND SUPPLY OF MEDICINES 48A. Licensing of manufacture and wholesale dealing 48B. Exemptions from licensing 48C. Application for manufacturer's or wholesale licence 48D. Factors relevant to determination of application 48E. Persons qualified for grant of manufacturer's licences 48F. Grant or refusal of licence 48G. Duration and renewal of licence 48x. Suspension, variation and revocation of manufacturer's or wholesale licences 481. Variation of manufacturer's or wholesale licence on application of holder 481. Appeals 48K. Inspection and search of premises, etc. 481.. Offences 49. Sale of medicines 50. Medicine Licence 51. Animal Medicine Licence 52. Police to be notified of issue of licence 53. Only medicines mentioned in licence may be sold 54. (Repealed) Cap. 115 Rev. 1985 Pharmacy and Poisons 5 55. Adulteration of medicines 56. Sale of adulterated medicines 57. Offence in relation to sales 58. Reliance on written warranty a good defence 59. Importation of medicines 60. Labels on medicines imported 61. Importation of certain medicines may be prohibited PART VI-POISONS 62. Importation and sale of poisons 63. Pharmacists to be authorised sellers of poisons 64. Poisons Licence 65. Register of Premises 66. Prohibition and regulations with respect to the sale of poisons 67. Exemption with respect to medicines 68. Exemption with respect to certain sales 69. Use of titles, emblems and descriptions 70. Prohibition of sale of poisons by means of automatic machine PART VII-MISCELLANEOUS 71. Regulations 72. General penalty 73. Application of Customs law First Schedule-Countries, etc., Specified for the Purpose of Section 22 Second Schedule-Exempted Articles Third Schedule-The Poisons List Fourth Schedule-Animal Medicines Ordinances Nos. 30 of1937, 22 of1938, Order in Council No. 4of1938, Ordinances Nos. 2 of 1945, 1 of1951, 9 of1955, Order 12 September 1957, Ordinance No. 5 of 1958, Order 31 March 1959, Ordinances Nos . 20 of 1960, 32 of 1962, Order 22 March 1965, Ordinances Nos. 37 of1966, 52 of1968, 11 of1970, Legal Notices Nos. 112 of1970, 118 of1970, 58 of1971, 104 of1971, 59 of1973, 28 of1975, Acts Nos . 14 of 1975, 24 of 1976, Legal Notice No. 124 of 1977, Acts Nos. 2 of 1980, 18 of 1984, Legal Notices Nos. 155 of 1980, 180 of1980,12 of1981,35 of1983, 36of1983 AN ACT TO PROVIDE FOR THE REGISTRATION OF PHARMACISTS AND TO CONTROL THE PRACTICE OF PHARMACY AND THE SALE AND DISTRIBUTION OF DRUGS AND POISONS AND FOR PURPOSES CONSEQUENTIAL THEREON [1 January 19381 PART I-PRELIMINARY Short title 1 . This Act may be cited as the Pharmacy and Poisons Act. 6 Pharmacy and Poisons Cap. 115 Rev. 1985 Interpretation 2.-(1) In this Act, unless the context otherwise requires- "administer" in relation to any substance or article means administer it either in its existing state or after it has been dissolved or dispersed in, or diluted or mixed with, some other substance used as a vehicle ; "assembly" in relation to a medicine, means the process of enclosing the medicine in a container which is labelled before the medicine is sold or offered for sale, or where the medicine is already enclosed in the container in which it is to be sold or offered for sale, labelling the container before the medicine is sold or offered for sale in it; "Board" means the Pharmacy and Poisons Board appointed under this Act; "chairman" means the chairman of the Board appointed under this Act; "manufacture" in relation to a medicine, includes any process carried out in the course of making the medicine including the assembly thereof, but does not include dissolving or dispersing the medicine in, or diluting or mixing it with, some other substance used as a vehicle for the purpose of administering it and does not include the incorporation of the medicine in any animal feeding stuff; "medicine" and "medicinal purpose" have the meanings assigned to them by section 2A ; "member" means a member of the Board constituted under this Act ; "Permanent Secretary" means the Permanent Secretary for Health; "poison" includes the several substances mentioned in the Poisons List in the Third Schedule; "qualified veterinary surgeon" means any veterinary surgeon registered under the provisions of the 'Veterinary Surgeons Act; (Cap. 257.) "register" means the Register of Pharmacists registered under this Act; "registered dentist" means a dentist registered under the Medical and Dental Practitioners Act; (Cap. 255.) "registered medical practitioner" or "medical practitioner" or "duly qualified practitioner" means a medical practitioner registered under the Medical and Dental Practitioners Act; (cap. 255.) "registered pharmacist" means a person registered under the provisions of this Act. (Amended by Ordinance 5 of 1958, s. 2; 32 of 1962, s. 2; 37 of 1966, s. 39; Act 14 of 1975, s. 26; 2 of 1980, s. 2.) (2) In this Act any reference to selling anything by way of wholesale dealing is a reference to selling it to a person who buys it for the purpose of- (a) selling or supplying it; or (b) administering it or causing it to be administered to one or more human beings, in the course of a business carried on by that person, except that it does not include any such sale by the person who manufactured it under and in accordance with a manufacturer's licence. (Inserted by Act 2 of 1980, s. 2.) Cap. 115 Rev. 1985 Pharmacy and Poisons 7 Meaning of "medicine" and related expressions 2A.-(1) In this Act- (a) "medicine" means any substance or article (not being an instrument, apparatus or appliance) which is manufactured, sold or offered for sale for use wholly or mainly in either or both of the following ways: (i) use by being administered to human beings or animals for a medicinal purpose; (ii) use, in circumstances specified in subsection (2), as an ingredient in the preparation of a substance or article which is to be administered to human beings or animals for a medicinal purpose, but, except as provided in section 2s, medicine does not include a substance or article the sole or principal use of which is, or ordinarily is, a cosmetic use, or which is represented to be, or might reasonably be taken to be, for cosmetic use; (b) "medicinal purpose" means any one or more of the following purposes : (i) treating or preventing a disease; (ii) diagnosing disease or ascertaining the existence, degree or extent of a physiological condition; (iii) contraception ; (iv) inducing anaesthesia ; (v) otherwise preventing or interfering with the normal operation of a physiological function, whether permanently or tempor- arily, and whether by way of terminating, reducing or postponing, or increasing or accelerating, the operation of that function or in any other way. (2) The circumstances referred to in subsection (1) (a) (ii) are- a) use in a pharmacy or in a hospital, clinic, nursing home or similar institution; (b) use by a medical practitioner, registered dentist, registered pharmacist or a qualified veterinary surgeon; (c) use in the course of a business which consists of or includes the retail sale of herbal remedies . (3) In subsection (2) (c) "herbal remedy" means a medicine consisting of a substance produced by subjecting a plant to drying, crushing or any other process, or of a mixture whose sole ingredients are two or more substances so produced, or of a mixture whose sole ingredients are one or more substances so produced and water or some other inert substance. (Inserted by Act 2 of 1980, s. 3.) Certain substances or articles to be treated as medicines 2s.-(1) Where in the course of trade or business any substance or article is manufactured, sold or offered for sale as a medicine or is described as a medicine or recommended in any manner to be used for a medicinal purpose that substance or article shall be treated as a medicine for the purposes of this Act.
Recommended publications
  • Postoperative Vomiting: a Review and Present Status of Treatment

    Postoperative Vomiting: a Review and Present Status of Treatment

    POSTOPERATIVE VOMITING: A REVIEW ~ND ~?RESENT STATUS OF TREATMENT* L. E. SI2vlONSEN, M.D., C.NI., and S. L. VANDEWAjTER,M.D., r.R.c.r. (c.) t POSTOPERATIVE VO~vlITING remains one of the most I frequent complications en- countered by the anaesthetist. Although considered no|more than a nuisance complication, it can, in certain cases, contribute to more ~lSan just discomfort for the patient; it can threaten his very life either immediately through aspiration, or later by serious loss bf fluids and electrolytes. It cap also add considerable strain on some operation wounds. After Wang and Boxison 1 further delineated the vomit ng centre in 1952, most of the succeeding research and investigation into the ~ontrol of vomiting has centred about those drugs that have a depressant actio 1 on the chemoreceptor trigger zone (C.T.Z.). Out of these investigations have c ~me much valuable and interesting data which the anaesthetist may use as additio ns to his ever-expanding resources to provide safety and comfort to the surgical patient. THE VOMXTn~OCENTaE Neurophysiologists have long accepted the existence of a vomiting centre. Located in the medulla in the solitary tract and the dgrsal part of the lateral reticular formation, it lies in close relationship to ma:ay other centres whose functions are associated with the vomiting act such ts salivation, spasmodic respiratory movements, and forced inspiration. ~ Lying lorsolateral to the vagal nuclei and close to the vomiting centre in the area pos :rema of thefloor of the fourth ventricle is an accessory vomiting centre which Ihas been designated as the C.T.Z.
  • Download Download

    Download Download

    J. Pharm. Tech. Res. Management Vol. 8, No. 1 (2020), pp.39–46 Vol. 7 | No. 2 | Nov 2019 Journal of Pharmaceutical Technology Research and Management Journal homepage: https://jptrm.chitkara.edu.in/ Ranitidine Induced Hepatotoxicity: A Review Amit Bandyopadhyay Banerjee1, Manisha Gupta2, Thakur Gurjeet Singh3, Sandeep Arora4 and Onkar Bedi5* Chitkara College of Pharmacy, Chitkara University, Punjab-140401, India [email protected] [email protected] [email protected] [email protected] 5*[email protected] (Corresponding Author) ARTICLE INFORMATION ABSTRACT Received: January 29, 2020 Background: Ranitidine (RAN) is one of the common drugs associated with idiosyncratic Revised: April 08, 2020 adverse drug reactions (IADRs) in humans. It was found to be associated with severe adverse drug Accepted: April 28, 2020 reactions due to the presence of contaminants such as N-Nitrosodimethylamine (NDMA) which Published Online: May 20, 2020 is claimed to be carcinogenic. As a consequence, on April 1, 2020, United States Food and Drug Keywords: Administration (USFDA) had decided to call off all the RAN products from the market. The exact DILI, Ranitidine withdrawal, RAN induced cause of RAN associated idiosyncratic hepatotoxicity is not clear yet. hepatotoxicity Purpose: To summarize and analyze the reason behind the withdrawal of RAN products from the market and whether ranitidine will be available again in future or will FDA withdraw approvals of ranitidine National Drug Authority (NDA) and an abbreviated new drug application (ANDA)? Methods: We performed a systematic PubMed/MEDLINE search of studies investigating the reason behind the withdrawal of RAN products and explored the possible mechanism associated with RAN induced hepatotoxicity.
  • Prohibited Substances List

    Prohibited Substances List

    Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR). Neither the List nor the EADCM Regulations are in current usage. Both come into effect on 1 January 2010. The current list of FEI prohibited substances remains in effect until 31 December 2009 and can be found at Annex II Vet Regs (11th edition) Changes in this List : Shaded row means that either removed or allowed at certain limits only SUBSTANCE ACTIVITY Banned Substances 1 Acebutolol Beta blocker 2 Acefylline Bronchodilator 3 Acemetacin NSAID 4 Acenocoumarol Anticoagulant 5 Acetanilid Analgesic/anti-pyretic 6 Acetohexamide Pancreatic stimulant 7 Acetominophen (Paracetamol) Analgesic/anti-pyretic 8 Acetophenazine Antipsychotic 9 Acetylmorphine Narcotic 10 Adinazolam Anxiolytic 11 Adiphenine Anti-spasmodic 12 Adrafinil Stimulant 13 Adrenaline Stimulant 14 Adrenochrome Haemostatic 15 Alclofenac NSAID 16 Alcuronium Muscle relaxant 17 Aldosterone Hormone 18 Alfentanil Narcotic 19 Allopurinol Xanthine oxidase inhibitor (anti-hyperuricaemia) 20 Almotriptan 5 HT agonist (anti-migraine) 21 Alphadolone acetate Neurosteriod 22 Alphaprodine Opiod analgesic 23 Alpidem Anxiolytic 24 Alprazolam Anxiolytic 25 Alprenolol Beta blocker 26 Althesin IV anaesthetic 27 Althiazide Diuretic 28 Altrenogest (in males and gelidngs) Oestrus suppression 29 Alverine Antispasmodic 30 Amantadine Dopaminergic 31 Ambenonium Cholinesterase inhibition 32 Ambucetamide Antispasmodic 33 Amethocaine Local anaesthetic 34 Amfepramone Stimulant 35 Amfetaminil Stimulant 36 Amidephrine Vasoconstrictor 37 Amiloride Diuretic 1 Prohibited Substances List This is the Equine Prohibited Substances List that was voted in at the FEI General Assembly in November 2009 alongside the new Equine Anti-Doping and Controlled Medication Regulations(EADCMR).
  • Attendee Guidelines

    Attendee Guidelines

    (Temple of Eternal Sound) Attendee Guidelines 1. Introduction 2. Practical Guidelines -Preparation -Contraindications -Food -Clothing -Cleansing -During the Session -Suggested Best Practices -Temple Practices & Ritual Norms -Single Sacrament Sanctuary 3. Code of Ethics 4. Dietary Guidelines 5. Medical Information 6. Attendee Waiver Céu do Som Welcome, Thank you for your interest in our Forest Family Circles, Realisation Retreats and Wisdom Works at the Temple of Céu do Som & Abuelatree Sanctuary. You are endeavouring to participate in what, for us, is one of the most profound and meaningful doorways into the mysteries of the Sacred & Profound. The following pages are practical suggestions outlining our expectations, guidelines and safety measures to ensure harmony for you, for our work and for our community. We seek to uphold a high standard in regards to the safe space of transformation and realisation that may create a positive impact through healing and integration of our participants. The guidelines in this booklet all serve a direct purpose. We ask that each one be approached with due respect. It is not necessary to subscribe to our points of view in order to receive the sacrament. We do not discriminate and find that ultimately it is up to the individual to discover what is true for them. Así Céu do Som PRACTICAL GUIDELINES Preparation for the spiritual study Contraindications (refer to Medical Information section for more details) 1. If you are uncertain about any contraindications or factors please ask. 2. If you have any personal concerns a meeting can be arranged prior in order to discuss. 3. If you are taking any prescription medication, namely antidepressants, antipsychotics or SSRI's please speak to us (Refer to Medical Information section).
  • The Use of Animals for Research in the Pharmaceutical Industry

    The Use of Animals for Research in the Pharmaceutical Industry

    Chapter 8 The use of animals for research in the pharmaceutical industry The ethics of research involving animals The use of animals for research in the CHAPTER 8 pharmaceutical industry Introduction THE USE OF ANIMALS FOR RESEARCH IN PHARMACEUTICAL INDUSTRY 8.1 The pharmaceutical industry conducts or supports approximately one third of the animal research that is undertaken in the UK. Some of this is basic research that seeks to examine normal biological processes and the nature of disease (see also Chapters 5 and 6). However, most has more specific, applied objectives and concerns the development of new medicines or vaccines, improved diagnosis or better methods of toxicity testing. Since the process of producing medicines has changed significantly over time, we begin with a brief overview of developments from the late 19th century to the present. We then describe the way medicines are currently produced in terms of eight stages. These are: discovery and selection of compounds that could be effective medicines (stages 1 and 2), characterisation of promising candidate medicines (stages 3 and 4), selecting candidate medicines and ensuring their safety (stage 5), clinical studies on humans (stages 6 to 8), and also research carried out to support the medicine once it has been marketed. For each stage we describe the way in which animals are used in the process, and give some examples of specific experiments. As in the case of research described in the previous chapters, welfare implications for the animals involved in pharmaceutical research are as diverse as the types of research and must be considered on a case by case basis.
  • High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury

    High Daily Dose and Being a Substrate of Cytochrome P450 Enzymes Are Two Important Predictors of Drug-Induced Liver Injury

    DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 DMD FastThis Forward.article has not Published been copyedited on and January formatted. 24, The 2014final version as doi:10.1124/dmd.113.056267 may differ from this version. DMD #56267 High daily dose and being a substrate of Cytochrome P450 enzymes are two important predictors of drug-induced liver injury Ke Yu, Xingchao Geng, Minjun Chen, Jie Zhang, Bingshun Wang, Katarina Ilic and Weida Tong Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, Downloaded from US Food and Drug Administration, Jefferson, AR, USA (K.Y., M.C., J.Z., W.T) National Center for Safety Evaluation of Drugs, National Institute for Food and Drug Control, China's State Food and Drug Administration, Beijing, China (X.G.) dmd.aspetjournals.org Department of Biostatistics, Shanghai Jiao Tong University School of Medicine, Shanghai, China (B.W.) Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, Belgrade, Serbia (K.I.) at ASPET Journals on September 24, 2021 1 Copyright 2014 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on January 24, 2014 as DOI: 10.1124/dmd.113.056267 This article has not been copyedited and formatted. The final version may differ from this version. DMD #56267 Running title: Two important predictors for drug-induced liver injury Corresponding authors: Katarina Ilic, Department of Pharmacology, Faculty of Pharmacy, University of Belgrade, 450 Vojvode Stepe, Belgrade 11221, Serbia. E-mail address: [email protected]. Weida Tong, Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, US Food and Drug Administration, 3900 NCTR Road, Jefferson, Downloaded from AR 72079, USA.
  • (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff Et Al

    (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff Et Al

    US006528521B2 (12) United States Patent (10) Patent No.: US 6,528,521 B2 Ruff et al. (45) Date of Patent: Mar. 4, 2003 (54) TREATMENT OF ANTI-DEPRESSION DRUG- 5,756.483. A 5/1998 Merkus ....................... 514/58 INDUCED SEXUAL DYSFUNCTION WITH 5,770,606 A 6/1998 El-Rashidy et al. ........ 514/284 APOMORPHINE 5,866,164 A 2/1999 Kuczynski et al. ......... 424/472 5,897.864. A 4/1999 Cohen ..................... 424/195.1 5,939,094. A 8/1999 Durif et al. ................. 424/448 (75) Inventors: 3. P slot, NSS). 5,945,117 A 8/1999 El-Rashidy et al. ........ 424/430 (73) Assignee: Tap Pharmaceutical Products, Inc., OTHER PUBLICATIONS Lake Forest, IL (US) Marketletter of Jul. 17, 1995 (abstract).* (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 Wilson, E.K., Chemical & Engineering News, 76(26), pp. 29 U.S.C. 154(b) by 0 days. (Jun. 29, 1998). (21) Appl. No.: 09/993,782 * cited by examiner (22) Filed: Nov. 14, 2001 O O Primary Examiner Phyllis G. Spivack (65) Prior Publication Data (74) Attorney, Agent, or Firm- Wood, Phillips, Katz, Clark US 2002/0115683 A1 Aug. 22, 2002 & Mortimer Related U.S. Application Data (57) ABSTRACT (60) Provisional application No. 60/249,031, filed on Nov. 15, A method for treating Sexual dysfunction that is caused by 2000. anti-depressant medication in a patient in need of Such (51) Int. Cl. .............................................. A61K 31/473 treatment, comprising administering a therapeutically effec (52) U.S. Cl. ....................................................... 5141284 tive amount of apomorphine, or a pharmaceutically accept (58) Field of Search .........................................
  • Hydroxylamines and Hydrazines As Surrogates of Sp3 Carbons in Medicinal Chemistry

    Hydroxylamines and Hydrazines As Surrogates of Sp3 Carbons in Medicinal Chemistry

    Wayne State University Wayne State University Dissertations January 2018 Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry Sandeep Dhanju Wayne State University, [email protected] Follow this and additional works at: https://digitalcommons.wayne.edu/oa_dissertations Part of the Chemistry Commons Recommended Citation Dhanju, Sandeep, "Hydroxylamines And Hydrazines As Surrogates Of Sp3 Carbons In Medicinal Chemistry" (2018). Wayne State University Dissertations. 2156. https://digitalcommons.wayne.edu/oa_dissertations/2156 This Open Access Dissertation is brought to you for free and open access by DigitalCommons@WayneState. It has been accepted for inclusion in Wayne State University Dissertations by an authorized administrator of DigitalCommons@WayneState. HYDROXYLAMINES AND HYDRAZINES AS SURROGATES OF SP3 CARBONS IN MEDICINAL CHEMISTRY by SANDEEP DHANJU DISSERTATION Submitted to the Graduate School of Wayne State University, Detroit, Michigan in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY 2019 MAJOR: CHEMISTRY (Organic) Approved By: Advisor Date DEDICATION I dedicate my PhD work to my parents Sanubhai Shrestha and Punamaya Dhanju, for their endless love and support. ii ACKNOWLEDGEMENTS First and foremost, I would like to express my sincere gratitude to my Ph.D. advisor Prof. David Crich for his incessant support and guidance for my Ph.D. research work during the past five years in his laboratory. I am grateful and fortunate to be one of his graduate students. His encouragement and motivation drove me to the end of this thesis, and I was able to develop an in-depth knowledge and enthusiasm in the areas of organic chemistry and medicinal chemistry. I would like to extend my gratitude to Prof.
  • | Hao Wanat Ha Maria Del Mar Man Unit Minit

    | Hao Wanat Ha Maria Del Mar Man Unit Minit

    |HAO WANAT HA MARIAUS009731026B2 DEL MAR MAN UNIT MINIT (12 ) United States Patent ( 10 ) Patent No. : US 9 ,731 , 026 B2 Su et al. (45 ) Date of Patent: Aug. 15 , 2017 ( 54 ) NEAT LIQUID PHARMACEUTICAL (58 ) Field of Classification Search FORMULATIONS ??? . .. A61K 8 /02 See application file for complete search history . @( 71) Applicant : Massachusetts Institute of Technology , Cambridge, MA (US ) (56 ) References Cited U . S . PATENT DOCUMENTS @( 72 ) Inventors : Erzheng Su , Cambridge, MA (US ) ; Alexander M . Klibanov , Boston , MA 3 , 800 ,038 A 3 / 1974 Rudel ( US ) 5 ,405 ,617 A 4 / 1995 Gowan 7 , 763 ,653 B2 7 / 2010 Pacheco @( 73 ) Assignee : Massachusetts Institute of 2009/ 0004281 Al * 1 / 2009 Nghiem . .. .. .. .. A61K 9 / 0004 Technology , Cambridge , MA (US ) 424 /490 @( * ) Notice : Subject to any disclaimer , the term of this OTHER PUBLICATIONS patent is extended or adjusted under 35 U . S . C . 154 ( b ) by 0 days . Abbott , et al ., “ Novel solvent properties of choline chloride /urea mixtures " , Chem . Commun . , 1 : 70 - 71 ( 2003 ) . Abbott, et al. , “ Ionic liquid analogues formed from hydrated metal ( 21 ) Appl. No. : 14 / 951, 055 salts ” , Chem . , Eur. J . , 10 : 3769 -74 ( 2004 ) . Bica , et al ., “ Liquid forms of pharmaceutical co -crystals : Exploring (22 ) Filed : Nov . 24 , 2015 the boundaries of salt formation ” , Chem Comm ., 47 ( 8 ) : 2267- 9 ( 2011 ) . (65 ) Prior Publication Data Grodowska , et al. , “ Organic solvents in the pharmaceutical indus US 2016 / 0143848 A1 May 26 , 2016 try ” , Acta Polomine Pharma. , 67 ( 1 ) : 3 - 12 (2010 ) . International Search Report for Corresponding PCT/ US2015 / Related U . S . Application Data 062470 mailed Feb . 3 , 2016 .
  • The Action of Thiethylperazihe Torecan®), a New Anti-Emetic, Compared

    The Action of Thiethylperazihe Torecan®), a New Anti-Emetic, Compared

    TH,'E ACTION OFf THIETHYLPERAZI!~Ei: ~ITO!~ECANr A NE'~( ANTI''-- EMETIC, COMPARED,' WITH:". PER[P:NHE' i ' q[AZINE ' ( TRILAFON|:'1 L TR~METHOBENZAMIDE (TIGAN| AND[A PI.ACE~O IN THE" suPPRESSION OF POSTANAESTHETI~NAIUSEN AND V()MITING IAN E. PtrnICIS, M.B., B.S., ~.F.A..I~.C.S.O POSTa_Na_ESTH~TIC VOMITING has been ~shown ~0 b(l" i~ffffeneed ]~y a varie]ty of factors, and it is therefore unlikely that any a~i-ergetie drug will be completely effective and without side-effects in all patients. In[the absence of any ele~r-eut superiority of one drug over another,-the physi4ian naust exercise a choicK selecting a drug with minimum side-effects but maximum anti-emetic effect. This choice can only be made on the basis of ieontrolled studies of effectir and side-effects, since clinical impressions can be nlost misleading.~ Malay ~igents can be shown to have an anti-emetic effect wl~n e0mpared I with a placebo (e.g., atropine) 1 but they may not be clinically us,~fuI as anfi-erneties. If new drug can be shown to have an effect equal to ~or better than a drug whi, .a has proven highly effective against a strong clinica,l challenge, then it is likeb that the new agent will be clinically useful. Thiethylperazine (Toreean| is a phenothiazin Which possesses to a very marked degree the anti-emetic activity common to all drugs, of this group, while the other group activities of lowering bk od pressure,~=.potentiatign of narcotics and barbil~urates, and extrapyramidal et feets, are minimized.
  • (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al

    (12) United States Patent (10) Patent No.: US 9,526,704 B2 Bosse Et Al

    USO09526704B2 (12) United States Patent (10) Patent No.: US 9,526,704 B2 BOSse et al. (45) Date of Patent: *Dec. 27, 2016 (54) PHARMACEUTICAL COMPOSITIONS FOR A6IR 9/24 (2006.01) TREATING OR PREVENTING PAN A69/20 (2006.01) (52) U.S. Cl. (71) Applicant: LOCL Pharma, Inc., Las Vegas, NV CPC ............. A61K 9/209 (2013.01); A61 K9/2013 (US) (2013.01); A61 K9/2054 (2013.01); A61 K 3 1/167 (2013.01); A61K 31/485 (2013.01); (72) Inventors: Paul Bosse, Jupiter, FL (US); John A61K 3.1/5415 (2013.01) Ameling, Jupiter, FL (US); Bernard (58) Field of Classification Search Schachtel, Jupiter, FL (US); Ray CPC A61K 2300/00; A61K 31/167; A61K 31/485; Takigiku, Loveland, OH (US) A61K 3.1/5415: A61 K9/2054: A61 K 9/209 (73) Assignee: LOCL PHARMA, INC., Las Vegas, See application file for complete search history. NV (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 0 days. 3,048,526 A 8/1962 Boswell This patent is Subject to a terminal dis- 3,108,046 A 10/1963 Harbit claimer. (Continued) (21) Appl. No.: 15/206.955 FOREIGN PATENT DOCUMENTS 1-1. CA 2262267 A1 8, 1999 (22) Filed: Jul. 11, 2016 DE 102005O13726 A1 9, 2006 (65) Prior Publication Data (Continued) US 2016/0317447 A1 Nov. 3, 2O16 OTHER PUBLICATIONS Related U.S. Application Data US 8.975,271, 03/2015, Oshlack et al.
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0065861 A1 Wu Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0065861 A1 Wu Et Al

    US 2013 OO65861A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0065861 A1 Wu et al. (43) Pub. Date: Mar. 14, 2013 (54) COMPOUNDS (CYSTEIN BASED Publication Classification LIPOPEPTIDES) AND COMPOSITIONS AS (51) Int. Cl. TLR2AGONSTS USED FORTREATING A63L/23 (2006.01) INFECTIONS, INFLAMMATIONS, A6IP II/06 (2006.01) RESPRATORY DISEASESETC. A6IP II/00 (2006.01) A6IPL/04 (2006.01) A6IPI/00 (2006.01) A6IP35/00 (2006.01) (75) Inventors: Tom Yao-Hsiang Wu, San Diego, CA A6IP 9/02 (2006.01) (US); Yefen Zou, San Diego, CA (US); C07F 9/40 (2006.01) Timothy Z. Hoffman, San Diego, CA A6IP3 L/18 (2006.01) (US); Jianfeng Pan, San Diego, CA A63/662 (2006.01) C07D 213/56 (2006.01) (US) A613 L/4402 (2006.01) C07C 237/06 (2006.01) C07D 265/30 (2006.01) (73) Assignee: IRM LLC, Hamiltona (BM) A 6LX3/5.375 (2006.01) C07D 233/6 (2006.01) (21) Appl. No.: 13/636,328 A613 L/4164 (2006.01) C07C 237/04 (2006.01) PCT Fled: Mar. 23, 2011 (52) U.S. Cl. (22) USPC ........... 514/119:554/101: 514/548; 546/335; 514/357: 514/547: 544/159; 514/237.8: 548/338.5; (86) PCT NO.: PCT/US11A29661 514/399 S371 (c)(1), (57) ABSTRACT (2), (4) Date: Sep. 20, 2012 The invention provides a novel class of compounds viz. gen erally lipopeptides like Pam3CSK4, immunogenic composi tions and pharmaceutical compositions comprising Such Related U.S. Application Data compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like (60) Provisional application No.